A 64-year-old man with type 2 diabetes, an HbA1c of 8.2%, and established coronary artery disease is on metformin and lifestyle therapy. His eGFR is 55 mL/min/1.73 m², and albumin-to-creatinine ratio is 8 mg/mmol. According to the 2024 Diabetes Canada pharmacologic update, which additional class of glucose-lowering agent is preferred to improve both glycaemic control and cardiovascular outcomes?